Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Amanda Darekar

Showing results (1-10 of 25) with videos related to

Pageof 3
Sort By:
Neurourology and Urodynamics|April 8, 2014
Factors associated with dose escalation of fesoterodine for treatment of overactive bladder in people >65 years of age: A post hoc analysis of data from the SOFIA studyAdrian Wagg, Amanda Darekar, Daniel Arumi, et al.
International Urogynecology Journal|November 22, 2013
Effect of fesoterodine on urethral closure function in women with stress urinary incontinence assessed by urethral pressure reflectometryNiels Klarskov, Amanda Darekar, David Scholfield, et al.
Neurourology and Urodynamics|October 2, 2010
Investigation of the clinical efficacy and safety of pregabalin alone or combined with tolterodine in female subjects with idiopathic overactive bladderJosef Marencak, Nandini H Cossons, Amanda Darekar, et al.
Cardiovascular Diabetology|May 9, 2019
Effect of ertugliflozin on blood pressure in patients with type 2 diabetes mellitus: a post hoc pooled analysis of randomized controlled trialsJie Liu, Annpey Pong, Silvina Gallo, et al.
Diabetes, Obesity & Metabolism|February 9, 2018
Long-term efficacy and safety of ertugliflozin monotherapy in patients with inadequately controlled T2DM despite diet and exercise: VERTIS MONO extension studyRonnie Aronson, Juan Frias, Allison Goldman, et al.
Human Psychopharmacology|September 5, 2006
Cognitive testing in early phase clinical trials: outcome according to adverse event profile in a Phase I studyAlex Collie, Paul Maruff, Peter J Snyder, et al.
European Journal of Drug Metabolism and Pharmacokinetics|March 9, 2023
Population Pharmacokinetic and Pharmacodynamic Modeling of Fesoterodine in Pediatric Patients with Neurogenic Detrusor OveractivityYamato Sano, Satoshi Shoji, Mohamed Shahin, et al.
Neurourology and Urodynamics|March 6, 2013
Long-term safety, tolerability and efficacy of flexible-dose fesoterodine in elderly patients with overactive bladder: open-label extension of the SOFIA trialAdrian Wagg, Vik Khullar, Martin C Michel, et al.
Contemporary Clinical Trials|October 1, 2016
Development of a predictive model for urgency urinary incontinenceAmanda Darekar, Martin Carlsson, Sheila Quinn, et al.
International Urogynecology Journal|May 12, 2012
Safety and efficacy of flexible-dose fesoterodine in British subjects with overactive bladder: insights into factors associated with dose escalationLinda Cardozo, Timothy Hall, John Ryan, et al.
Pageof 3

Showing results (1-10 of 25) with videos related to

Sort By:
Pageof 3
Neurourology and Urodynamics|April 8, 2014
Factors associated with dose escalation of fesoterodine for treatment of overactive bladder in people >65 years of age: A post hoc analysis of data from the SOFIA studyAdrian Wagg, Amanda Darekar, Daniel Arumi, et al.
International Urogynecology Journal|November 22, 2013
Effect of fesoterodine on urethral closure function in women with stress urinary incontinence assessed by urethral pressure reflectometryNiels Klarskov, Amanda Darekar, David Scholfield, et al.
Neurourology and Urodynamics|October 2, 2010
Investigation of the clinical efficacy and safety of pregabalin alone or combined with tolterodine in female subjects with idiopathic overactive bladderJosef Marencak, Nandini H Cossons, Amanda Darekar, et al.
Cardiovascular Diabetology|May 9, 2019
Effect of ertugliflozin on blood pressure in patients with type 2 diabetes mellitus: a post hoc pooled analysis of randomized controlled trialsJie Liu, Annpey Pong, Silvina Gallo, et al.
Diabetes, Obesity & Metabolism|February 9, 2018
Long-term efficacy and safety of ertugliflozin monotherapy in patients with inadequately controlled T2DM despite diet and exercise: VERTIS MONO extension studyRonnie Aronson, Juan Frias, Allison Goldman, et al.
Human Psychopharmacology|September 5, 2006
Cognitive testing in early phase clinical trials: outcome according to adverse event profile in a Phase I studyAlex Collie, Paul Maruff, Peter J Snyder, et al.
European Journal of Drug Metabolism and Pharmacokinetics|March 9, 2023
Population Pharmacokinetic and Pharmacodynamic Modeling of Fesoterodine in Pediatric Patients with Neurogenic Detrusor OveractivityYamato Sano, Satoshi Shoji, Mohamed Shahin, et al.
Neurourology and Urodynamics|March 6, 2013
Long-term safety, tolerability and efficacy of flexible-dose fesoterodine in elderly patients with overactive bladder: open-label extension of the SOFIA trialAdrian Wagg, Vik Khullar, Martin C Michel, et al.
Contemporary Clinical Trials|October 1, 2016
Development of a predictive model for urgency urinary incontinenceAmanda Darekar, Martin Carlsson, Sheila Quinn, et al.
International Urogynecology Journal|May 12, 2012
Safety and efficacy of flexible-dose fesoterodine in British subjects with overactive bladder: insights into factors associated with dose escalationLinda Cardozo, Timothy Hall, John Ryan, et al.
Pageof 3